Humacyte to Present Third Quarter Financial Results and Provide Business Update on November 12, 2025
Rhea-AI Summary
Humacyte (Nasdaq: HUMA) will release third quarter 2025 financial results for the period ended September 30, 2025 on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 AM Eastern Time to provide a corporate and financial update. The webcast will be accessible 15 minutes prior to the start time and a replay will be available on the company's investor website for at least 30 days.
Dial-in numbers are provided for U.S. and international investors and a conference ID is listed for access. The event covers the company’s corporate and financial update and is scheduled to coincide with the quarterly results release.
Positive
- None.
Negative
- None.
News Market Reaction 10 Alerts
On the day this news was published, HUMA declined 9.66%, reflecting a notable negative market reaction. Argus tracked a peak move of +4.6% during that session. Argus tracked a trough of -3.8% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $26M from the company's valuation, bringing the market cap to $242M at that time.
Data tracked by StockTitan Argus on the day of publication.
DURHAM, N.C., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the quarter ended September 30, 2025, on Wednesday, November 12, 2025. Management will host a webcast and conference call at 8:00 a.m. ET to provide a corporate and financial update.
| Title: | Humacyte Third Quarter 2025 Financial Results and Corporate Update |
| Date: | November 12, 2025 |
| Time: | 8:00 AM Eastern Time |
| Conference Call Details: | 1-877-704-4453 (U.S. Investors Dial) 1-201-389-0920 (International Investors Dial) 13756236 (Conference ID) |
| Call me™ Feature: | Click Here |
| Webcast: | Click Here |
The webcast should be accessible 15 minutes prior to the conference call’s start time. A replay of the webcast will be available following the conclusion of the live broadcast and will be accessible on the investors section of the Company’s website for at least 30 days.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received an RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
FAQ
When will Humacyte (HUMA) report Q3 2025 results?
What time is the Humacyte (HUMA) Q3 2025 webcast and call?
How can investors join the Humacyte (HUMA) conference call?
When will the Humacyte (HUMA) webcast be available to join?
Will Humacyte (HUMA) provide a replay of the Q3 2025 webcast?
Where can investors find materials from the Humacyte (HUMA) November 12, 2025 presentation?
